↓ Skip to main content

Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors

Overview of attention for article published in Neuropharmacology, April 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
6 X users
facebook
4 Facebook pages
reddit
1 Redditor

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors
Published in
Neuropharmacology, April 2014
DOI 10.1016/j.neuropharm.2014.03.014
Pubmed ID
Authors

Joëlle Nader, Cinzia Rapino, Benjamin Gennequin, Francois Chavant, Maureen Francheteau, Alexandros Makriyannis, Andrea Duranti, Mauro Maccarrone, Marcello Solinas, Nathalie Thiriet

Abstract

Methamphetamine toxicity is associated with cell death and loss of dopamine neuron terminals in the striatum similar to what is found in some neurodegenerative diseases. Conversely, the endocannabinoid system (ECS) has been suggested to be neuroprotective in the brain, and new pharmacological tools have been developed to increase their endogenous tone. In this study, we evaluated whether ECS stimulation could reduce the neurotoxicity of high doses of methamphetamine on the dopamine system. We found that methamphetamine alters the levels of the major endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) in the striatum, suggesting that the ECS participates in the brain responses to methamphetamine. Δ(9)-tetrahydrocannabinol (THC), a cannabis-derived agonist of both CB1 and CB2 cannabinoid receptors, or inhibitors of the main enzymes responsible for the degradation of AEA and 2-AG (URB597 and JZL184, respectively), blunted the decrease in striatal protein levels of tyrosine hydroxylase induced by methamphetamine. In addition, antagonists of CB2, but not of CB1, blocked the preventive effects of URB597 and JZL184, suggesting that only the former receptor subtype is engaged in neuroprotection exerted by ECS stimulation. Finally, we found that methamphetamine increases striatal levels of the cytokine tumor necrosis factor alpha, an effect that was blocked by ECS stimulation. Altogether, our results indicate that stimulation of ECS prior to the administration of an overdose of methamphetamine considerably reduces the neurotoxicity of the drug through CB2 receptor activation and highlight a protective function for the ECS against the toxicity induced by drugs and other external insults to the brain. This article is part of a Special Issue entitled 'CNS Stimulants'.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
United States 1 1%
Portugal 1 1%
Unknown 76 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 13%
Student > Bachelor 10 13%
Researcher 9 11%
Professor > Associate Professor 8 10%
Student > Doctoral Student 6 8%
Other 13 16%
Unknown 23 29%
Readers by discipline Count As %
Neuroscience 12 15%
Medicine and Dentistry 9 11%
Agricultural and Biological Sciences 8 10%
Psychology 5 6%
Social Sciences 5 6%
Other 10 13%
Unknown 30 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2024.
All research outputs
#6,443,044
of 25,373,627 outputs
Outputs from Neuropharmacology
#1,408
of 4,816 outputs
Outputs of similar age
#56,643
of 239,350 outputs
Outputs of similar age from Neuropharmacology
#5
of 23 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 4,816 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,350 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.